ANTX

Business Context and Reporting Period

Company: AN2 Therapeutics, Inc. (ANTX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: AN2 is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. The pipeline spans hematologic diseases, infectious diseases, and oncology. As of the reporting date, the company has no approved products and has not generated product revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Financing Activity: In March 2026, the company completed a Private Placement raising approximately $40.0 million gross ($37.2 million net) through the issuance of common stock and pre-funded warrants. Additionally, $1.4 million net was raised via At-The-Market (ATM) offerings during the six-month period.
• Liquidity Position: Total cash, cash equivalents, and investments increased from $59.9 million at December 31, 2025, to $79.9 million at June 30, 2026, driven primarily by the Private Placement proceeds.
• Expense Trends:
  • R&D Expenses: Increased 17% year-over-year for the six-month period ($12.8M vs $10.9M). This was driven by higher consulting, clinical trial, and preclinical study costs, partially offset by lower personnel expenses due to reduced stock-based compensation.
  • G&A Expenses: Decreased 15% year-over-year ($6.7M vs $7.9M), primarily due to lower stock-based compensation and professional service fees.
• Stock-Based Compensation: Total expense decreased to $2.4 million for the six months ended June 30, 2026, compared to $4.0 million in the prior year period. This reduction was influenced by a stock option repricing event in March 2026.

Guidance, Outlook, and Risks

• Outlook: Management believes current cash and investments ($79.9 million) are sufficient to fund operations for at least 12 months from the filing date. The company expects to incur substantial additional losses as it advances clinical trials.
• Clinical Pipeline Updates:
  • Epetraborole (Polycythemia Vera): Plans to expand Phase 2 study (EBO-PV-201) with an IND filing expected in Q3 2026 and enrollment anticipated in Q4 2026.
  • Epetraborole (M. abscessus): Supporting an investigator-initiated trial; topline results expected in late 2027.
  • AN2-502998 (Chagas Disease): Positive preclinical and Phase 1 data support a planned Phase 2 initiation in late 2026.
  • Melioidosis: Discussions are underway with the U.S. government to fund Phase 2 development.
• Material Weaknesses in Internal Controls: The company disclosed that material weaknesses in internal control over financial reporting identified in the prior year continue to exist as of June 30, 2026. These relate to insufficient accounting resources, lack of formal policies, and ineffective IT general controls.
• Risks: Significant risks include the failure of clinical trials, inability to raise additional capital, dependence on third-party manufacturers, and the potential for bacterial resistance to product candidates.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $79.9 million cash balance against the projected burn rate, given the company's history of significant operating losses and lack of revenue.
• Internal Controls: Assess the remediation plan for the continuing material weaknesses in financial reporting and IT controls, which pose a risk to the accuracy of future financial statements.
• Government Funding: Monitor the status of the NIAID contract for melioidosis, noting the $9.0 million reduction in contract funding announced in June 2025 and the reliance on non-dilutive funding for global health initiatives.
• Dilution: Review the impact of the 2026 Private Placement and outstanding pre-funded warrants (approx. 8.7 million shares) on existing shareholder equity.
• Clinical Milestones: Track the timeline for the Phase 2 IND filing for Polycythemia Vera and the initiation of the Chagas disease Phase 2 trial, as delays could materially impact capital requirements.